This article discusses various analytical techniques for quantifying alogliptin benzoate in pharmaceutical dosage forms and biological fluids. Alogliptin is considered one of the recent antidiabetic drugs acting by inhibition of dipeptidyl peptidase-4 enzyme where exopeptidase cleaves N-terminal dipeptides from a range of substrates, including as cytokines, growth factors, neuropeptides, and incretin hormones. Different analytical techniques will be discussed, including spectrophotometric (UV-visible), spectrofluorimetric, chromatographic (thin layer chromatography, capillary electrophoresis, high-performance liquid chromatography), and electrochemical methods. The HPLC methods have been used to determine alogliptin benzoate in pharmaceutical dosage forms or biological fluids, while other spectrophotometric, spectrofluorimetric, TLC, and capillary electrophoresis methods have been applied for pharmaceutical dosage forms. These methods are validated according to ICH guidelines for linearity, range, limit of detection, limit of quantification, accuracy, and precision. Furthermore, there is a graphical comparison between the proportion of each technique.